Patrick Starlinger
Overview
Explore the profile of Patrick Starlinger including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
107
Citations
1087
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Gudmundsdottir H, Graham R, Greipp P, Habermann E, Knudson R, Brandt C, et al.
J Neuroendocrinol
. 2025 Feb;
:e70003.
PMID: 39945220
Given the heterogeneous clinical behavior of pancreatic neuroendocrine tumors (pNETs), improved prognostic markers are needed to guide management and post-resection surveillance. Patients who underwent resection of large (≥3 cm) sporadic...
2.
Carey P, Pardanani A, Starlinger P, Tefferi A, Gangat N
Am J Hematol
. 2024 Dec;
100(3):527-530.
PMID: 39723660
No abstract available.
3.
Marell P, Kournoutas I, Gile J, Peersen A, Shah P, Babiker H, et al.
Oncologist
. 2024 Dec;
PMID: 39674576
Background: Atezolizumab plus bevacizumab (A/B) received FDA approval as the first-line therapy for patients with advanced hepatocellular carcinoma (HCC) in 2020. However, optimal subsequent treatment options are unclear. Here, we...
4.
Muaddi H, Glasgow A, Abou Chaar M, Habermann E, Starlinger P, Warner S, et al.
J Surg Oncol
. 2024 Dec;
PMID: 39628071
Background: Surgical resection for pancreas ductal adenocarcinoma (PDAC) remains the mainstay of treatment. Regardless of enhanced survival rates, disparities in patient outcomes and experiences driven by the social determinants of...
5.
Zhang C, Lu L, Hanson K, Sultan A, Starlinger P, Smoot R, et al.
Am Surg
. 2024 Nov;
:31348241304021.
PMID: 39612262
Background: Short-term outcomes after pancreatoduodenectomy (PD) are well-studied, but long-term reoperation rates and their indications remain poorly characterized. Methods: A single-center retrospective chart review was performed on patients who underwent...
6.
Pereyra D, Dingfelder J, Riha M, Kacar S, Rauter L, Becker N, et al.
Int J Surg
. 2024 Oct;
110(12):7909-7918.
PMID: 39422535
Background: Corroborating evidence for the use of hypothermic oxygenated machine perfusion (HOPE) prior to orthotopic liver transplantation (OLT) suggests a beneficial effect in regard to biliary complications. Here, the authors...
7.
Resch U, Hackl H, Pereyra D, Santol J, Brunnthaler L, Probst J, et al.
Int J Mol Sci
. 2024 Oct;
25(19).
PMID: 39409015
Methods: Our study included nine patients with hepatocellular carcinoma (HCC) undergoing PHx: three patients with PHLF, three patients undergoing the associating liver partition and portal vein ligation for staged hepatectomy...
8.
Santol J, Ammann M, Reese T, Oldhafer F, Dong Y, Schmelzle M, et al.
Eur J Surg Oncol
. 2024 Sep;
50(12):108696.
PMID: 39306501
No abstract available.
9.
Santol J, Pereyra D, Haegele S, Ammon D, Ortmayr G, Pirabe A, et al.
Gastro Hep Adv
. 2024 Aug;
2(5):642-651.
PMID: 39129875
Background And Aims: Activin A is a key regulator in liver regeneration, but data evaluating its role in humans after hepatic surgery are limited. In this study we explore the...
10.
Brunnthaler L, Hammond T, Pereyra D, Santol J, Probst J, Laferl V, et al.
Int J Mol Sci
. 2024 Jul;
25(13).
PMID: 39000266
Liver resection (LR) is the primary treatment for hepatic tumors, yet posthepatectomy liver failure (PHLF) remains a significant concern. While the precise etiology of PHLF remains elusive, dysregulated inflammatory processes...